References

Filters: Akiyama-2019b is   [Clear All Filters]
H
Hagan H, Pouget ER, Des-Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J of Epidemiol. 2008;168(10):1099-1109.
Hagström H. Alcohol consumption in concomitant liver disease: how much is too much?. Curr Hepatol Rep. 2017;16(2):152-157.
Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92(11):1789-1794.
Harris RJ, Martin NK, Rand E, et al. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat. 2016;23(8):631-643.
Harris, Jr. KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4(1):20-26.
Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med. 2001;134(2):120-124.
Harrison GI, Murray K, Gore R, et al. The hepatitis C awareness through to treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction. 2019;114(6):1113-1122.
Harrison DS, Giang J, Darling JM. An interaction between glecaprevir, pibrentasvir, and colchicine causing rhabdomyolysis in a patient with chronic renal disease. Clin Liver Dis (Hoboken). 2020;15(1):17-20.
Hashem M, Jhaveri R, Saleh DA, et al. Spontaneous viral load decline and subsequent clearance of chronic HCV in postpartum women correlates with favorable IL28B allele. Clin Infect Dis. 2017;65(6):999-1005.
Hattori Y, Orito E, Ohno T, et al. Loss of hepatitis C virus RNA after parturition in female patients with chronic HCV infection. J Med Virol. 2003;71(2):205-211.
Hayashi K, Ishigami M, Ishizu Y, Ishizu Y. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?. Clin J Gastroenterol. 2016;9(4):252-256.
He T, Li K, Roberts MS, et al. Prevention of hepatitis C by screening and treatment in US prisons. Ann Intern Med. 2016;164(2):84-92.
He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017;46(8):711-721.
Hegazi A, Lee M, Whittaker W, et al. Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics. Int J of STD AIDS. 2017;28(4):362-366.
Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. Hepatology. 2014;59(2):366-369.
Hellard ME, Jenkinson R, Higgs P, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust. 2012;196(10):638-641.
Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect. 2004;132(3):409-15.
Henderson DK, Dembry L, Fishman NO, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol. 2010;31(3):203-232.
Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89-94.
Herzer K, Papadopoulos-Kohn A, Walker A, et al. Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant. Digestion. 2015;91(4):326-333.
Top